APA (7th ed.) Citation

RR, Y., T, Z., Q, W., K, Y., J, L., & SH, G. (2021). Increased Serum Levels of Trypsin Inhibitor Kazal1 in Patients with HBV-Related Hepatocellular Carcinoma Predict a Poor Prognosis. Clinical laboratory, 67(1), . https://doi.org/10.7754/Clin.Lab.2020.200411

Chicago Style (17th ed.) Citation

RR, Yan, Zhu T, Wang Q, Yang K, Li J, and Guan SH. "Increased Serum Levels of Trypsin Inhibitor Kazal1 in Patients with HBV-Related Hepatocellular Carcinoma Predict a Poor Prognosis." Clinical Laboratory 67, no. 1 (2021). https://doi.org/10.7754/Clin.Lab.2020.200411.

MLA (9th ed.) Citation

RR, Yan, et al. "Increased Serum Levels of Trypsin Inhibitor Kazal1 in Patients with HBV-Related Hepatocellular Carcinoma Predict a Poor Prognosis." Clinical Laboratory, vol. 67, no. 1, 2021, https://doi.org/10.7754/Clin.Lab.2020.200411.